EDITAS MEDICINE INC. news, videos and press releases
For more news please use our advanced search feature.
EDITAS MEDICINE INC. - More news...
EDITAS MEDICINE INC. - More news...
- Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
- Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
- Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Announces Third Quarter 2024 Results and Business Updates
- Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
- Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
- Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
- Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Announces Second Quarter 2024 Results and Business Updates
- Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces First Quarter 2024 Results and Business Updates
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
- Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
- Editas Medicine Announces Third Quarter 2023 Results and Business Updates
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
